A Phase IIa randomized, double-blind, placebo-controlled study by Sofen et al. investigated the efficacy and safety of vixarelimab, a first-in-class fully human monoclonal antibody that targets the oncostatin M receptor (Figure 3b) in 49 participants with moderate-to-severe prurigo nodularis. The gene discussed is OSMR; the disease is prurigo nodularis.